RxSight Stock

rxsight.comHealthcare / Medical DevicesFunding to Date: $179.84MM

RxSight is the developer of the first and only adjustable intraocular lens (IOL) that is customized after cataract surgery, enabling doctors and patients to predictably optimize vision after cataract surgery through an office based IOL enhancement.

Register To Buy and Sell Shares

For more details on financing and valuation for RxSight, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access RxSight’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like RxSight.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Shelley Thunen
Chief Financial Officer
Robert Grubbs
Ronald Kurtz MD
Chief Executive Officer, President & Board Member
Christian Sandstedt Ph.D
Vice President, Optics Research & Development
Matthew Haller Ph.D
Chief Technology Officer
Eric Weinberg
Chief Commercial Officer

Board Members

Christopher Cox JD
Werner Wolfen
Javier Perez-Sala
Bruce Robertson Ph.D
H.I.G. BioHealth Partners
J. Corley
Ronald Kurtz MD
Juliet Bakker
Longitude Capital
Jan Bonel
Daniel Schwartz
William Link Ph.D
Flying L Partners
Joseph Devivo
James Adler

News Highlights

Calhoun Vision Raises $69M, Advances Novel Lenses for Cataract Patients
Venture investors are providing $69 million to Calhoun Vision Inc. and betting that its technology will make it stand out in a crowded market for artificial lenses used in cataract patients.
Updated on: Apr 22, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.